Compare AU
Compare CURE vs. F100
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Ftse 100 ETF (F100). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | F100 | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 44 |
Median incremental investment | $619.50 | $993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $4,648.80 |
Average age group | > 35 | > 35 |
Key Summary
CURE | F100 | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | F100.AX was created on 2019-07-12 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to track the price and income performance of the FTSE 100 Index (before fees and expenses). The Index provides exposure to the largest 100 comoanies traded on the London Stock Exchange, based on their market capitalisation. |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | ASTRAZENECA PLC (8.94 %) SHELL PLC (8.77 %) HSBC HOLDINGS PLC (6.17 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Financials (17.65 %) Consumer Staples (17.44 %) Energy (13.29 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United Kingdom of Great Britain and Northern Ireland (95.85 %) Switzerland (2.89 %) United States (0.96 %) |
Management fee | 0.45 % | 0.45 % |
Key Summary
CURE | F100 | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | FTSE 100 Index |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.45 % |
Price | $49.94 | $12.48 |
Size | $38.065 million | $340.912 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 3.01 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 16/07/2019 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | F100 | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 44 |
Median incremental investment | $619.50 | $993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $4,648.80 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | F100 | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | F100 |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |